Wenfei Luo^1,#, Dingming Song^2,#, Yibo He³, Judong Song^4,*, Yunzhen Ding^5,*

Oncology Research, Vol.33, No.8, pp. 1875-1893, 2025, DOI:10.32604/or.2025.063843 - 18 July 2025

Abstract Malignant melanoma, characterized by its high metastatic potential and resistance to conventional therapies, presents a major challenge in oncology. This review explores the current status and advancements in tumor vaccines for melanoma, focusing on peptide, DNA/RNA, dendritic cell, tumor cell, and neoantigen-based vaccines. Despite promising results, significant challenges remain, including the immunosuppressive tumor microenvironment, patient heterogeneity, and the need for more effective antigen presentation. Recent strategies, such as combining vaccines with immune checkpoint inhibitors (ICIs), aim to counteract immune evasion and enhance T cell responses. Emerging approaches, including personalized neoantigen vaccines and the use of More > Graphic Abstract

Ismail Bozkurt^1,*, Baris Yasar¹, Mehmet Baran Uslu², Nazan Bozdogan³

Oncologie, Vol.24, No.1, pp. 163-171, 2022, DOI:10.32604/oncologie.2022.019263 - 31 March 2022

Abstract Malignant melanoma caused by malignant transformation of melanocytes is associated with high mortality and is difficult to manage. Metastasis is not uncommon (up to 31% of all cases) and is closely associated with a poor prognosis. Although rare (4–5%), extracutaneous melanoma has been reported; however, primary malignant melanoma of the sacrum is extremely rare (only three case reports to date). Here, we present a 51-year-old patient who underwent surgical treatment for a lesion of the spinal canal and associated bony structures; extensive aggressive resection was required. She underwent partial sacrectomy and lumbo-iliac fixation (to maintain More >

Yankun Zhang^*, Wei Qian^*, Feng Feng^†, Qian Cao^*, Yanqi Li^*, Ying Hou^*, Luyang Zhang^*, Jufeng Fan^*

Oncology Research, Vol.27, No.3, pp. 371-377, 2019, DOI:10.3727/096504018X15178740729367

Abstract This study aimed to investigate the effect and underlying mechanism of lncRNA CASC2 in malignant melanoma (MM). Expression of CASC2 in MM tissues and cells was detected. A375 cells were transfected with pc-CASC2, si-CASC2, miR-18a-5p inhibitor, or corresponding controls, and then cell proliferation, migration, and invasion were detected using MTT assay, colony formation assay, and Transwell analysis, respectively. The relationship of miR-18a-5p and CASC2 or RUNX1 was detected by luciferase reporter assay. The levels of CASC2 and RUNX1 were significantly reduced in MM tissues compared with normal skin tissues or cells, while the miR-18a-5p level… More >

Munad Khan¹, Dermot O’Kane¹, Justin Du Plessis², Nathan Hoag¹, Nathan Lawrentschuk^1,3,4

Canadian Journal of Urology, Vol.23, No.1, pp. 8171-8175, 2016

Abstract Primary malignant melanoma of the urinary bladder is a rare lesion. We report the case of a 78-year-old male with no previous history of cutaneous melanoma who presented with hematuria. Further investigation with imaging and cystoscopy raised suspicion of a primary bladder and ureteric melanoma, which had subsequently metastasized. This was confirmed with histological assessment and a thorough search for alternative primary lesions. Unfortunately, our patient passed away prior to receiving any oncological treatment for his metastatic melanoma, underscoring both the high mortality of this lesionandtheneedforaconsensusondefnitivetreatment. More >

Di Yin^*†1, Yang Li^*1, Baofeng Guo^‡, Zhewen Liu^*, Yang Xu^§, Xiaoqin Wang^*, Yanwei Du^*, Libo Xu^*, Yan Meng^*, Xuejian Zhao^*, Ling Zhang^*

Oncology Research, Vol.23, No.5, pp. 229-236, 2015, DOI:10.3727/096504016X14550280421449

Abstract RNA interference (RNAi) has been used for cancer gene therapy in recent years. However, the application of RNAi is hindered in the absence of safe and efficient gene delivery. In this article, a novel vehicle of graphene oxide functionalized with polyethylenimine and polyethylene glycol (GO-PEI-PEG) was successfully synthetized and then used to deliver plasmid-based Stat3 siRNA. The carrier can readily bind plasmid with high transfection efficiency. Moreover, molecular biology studies reveal that Stat3-related gene and protein expressions were significantly inhibited, suggesting that the formation of GO-PEI-PEG complexes could be utilized as a promising gene delivery More >

Jean Wong, Gilbert J. Wise, Bradly Clark

Canadian Journal of Urology, Vol.15, No.2, pp. 4027-4029, 2008

Abstract Primary genitourinary melanoma accounts for less than 1% of all cases of melanoma. Melanoma of prostatic origin is extremely rare. These patients are difficult to diagnose and carry a very poor prognosis. Aggressive surgical resection is the current treatment standard. We report a case of primary malignant melanoma of the prostate found during transurethral resection of the prostate. More >

Jaime A. Wong, David G. Bell

Canadian Journal of Urology, Vol.13, No.2, pp. 3053-3056, 2006

Abstract Primary malignant melanoma of the prostate is very rare. Most cases attributed to the prostate actually originate from the prostatic urethra. Due to its infrequency, primary malignant melanoma of the genitourinary tract presents a difficult diagnostic and management challenge. We report a case of primary malignant melanoma of the prostate found incidentally following transurethral resection of the prostate (TURP). More >

Sero Andonian¹, Sarkis H. Meterissian¹, A. Kevin Watters², Antoine Loutfi¹

Canadian Journal of Urology, Vol.10, No.4, pp. 1947-1949, 2003

Abstract A 75 year-old uncircumcised man presented with a 1.1 mm thick malignant melanoma on the ventral aspect of the glans penis. He underwent isosulfan blue and technetium 99m guided sentinel lymph node (SLN) biopsy and distal penectomy with 2 cm margins. This is the third reported case of penile melanoma using both markers for SLN mapping. While frozen sections and H & E stains were negative, S-100 and HMB-45 immunohistochemistry revealed micrometastasis in one of the sentinel nodes. This case illustrates that any discussion with the patient about management and prognosis should await immunohistochemistry results. More >